Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck organon & Co. — Research and Development (R&D) ($M) ($M)
Organon & Co. Form 10-Q / 10-K
Latest, Q1 2022
96
Period ended Mar 31, 2022
Change on a year earlier
+43.3%
67 in Q1 2021
History
9 quarters
Since Q1 2020
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Organon & Co. — Research and Development (R&D) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q1 2022 | Mar 31, 2022 | 96 | +43.3% | Organon & Co. SEC Filing (0001821825-22-000006) ↗ |
| Q4 2021 | Dec 31, 2021 | 189 | +215.0% | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
| Q3 2021 | Sep 30, 2021 | 111 | +105.6% | Organon & Co. SEC Filing (0001628280-21-023199) ↗ |
| Q2 2021 | Jun 30, 2021 | 76 | +49.0% | Organon & Co. SEC Filing (0001821825-21-000009) ↗ |
| Q1 2021 | Mar 31, 2021 | 67 | +48.9% | Organon & Co. SEC Filing (0001821825-22-000006) ↗ |
| Q4 2020 | Dec 31, 2020 | 60 | – | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
| Q3 2020 | Sep 30, 2020 | 54 | – | Organon & Co. SEC Filing (0001628280-21-023199) ↗ |
| Q2 2020 | Jun 30, 2020 | 51 | – | Organon & Co. SEC Filing (0001821825-21-000009) ↗ |
| Q1 2020 | Mar 31, 2020 | 45 | – | Organon & Co. SEC Filing (0001821825-21-000005) ↗ |
Cite this data
StockData. (2026). Merck Organon & Co. — Research and Development (R&D) ($M) ($M), quarterly Q1 2020–Q1 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.